Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.40 |
| ▸ | FEN1 | P39748 | 1/20 | 0.40 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.36 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 3/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
| ▸ | KIF11 | P52732 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3096012 | 0.84 | CA2 (0.50) | CA2ALDH1A1TDP1PTGS1ALOX5AP | |
| SCHEMBL30921753 | 0.82 | CA2 (0.48) | CA2ALDH1A1TDP1PTGS1ALOX5AP | |
| SCHEMBL2957938 | 0.82 | CTSS (0.40) | ALDH1A1TDP1ADRA2BPTGS1TSHR | |
| SCHEMBL31347522 | 0.81 | TAAR1 (0.38) | ALDH1A1TDP1ADRA2BPTGS1TSHR | |
| Hydrochloric Acid SCHEMBL9279122 | 0.80 | CTSS (0.39) | ALDH1A1TDP1ADRA2BPTGS1SMN1; SMN2 | |
| SCHEMBL358326 | 0.79 | ALDH1A1 (0.52) | ALDH1A1TDP1ADRA2BPTGS1TSHR | |
| Hydrochloric Acid SCHEMBL4332744 | 0.77 | ALDH1A1 (0.50) | ALDH1A1TDP1ADRA2BPTGS1TSHR | |
| SCHEMBL31438691 | 0.77 | SMN1; SMN2 (0.47) | CA2ALDH1A1CYP3A4KDM4ESMN1; SMN2 | |
| SCHEMBL8417921 | 0.77 | SMN1; SMN2 (0.47) | CA2ALDH1A1CYP3A4KDM4ESMN1; SMN2 | |
| SCHEMBL6677826 | 0.77 | CA2 (0.43) | CA2ALDH1A1TDP1PTGS1ALOX5AP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210002233-A1 | PKM2 MODULATORS AND METHODS FOR THEIR USE | SUMITOMO PHARMA ONCOLOGY, INC. | 2021-01-07 | — | — | US | disclosed |
| US-10766865-B2 | PKM2 modulators and methods for their use | SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC. (US) | 2020-09-08 | — | — | US | disclosed |
| US-20200237766-A1 | PKM2 ACTIVATORS IN COMBINATION WITH REACTIVE OXYGEN SPECIES FOR TREATMENT OF CANCER | SUMITOMO PHARMA ONCOLOGY, INC. | 2020-07-30 | — | — | US | disclosed |
| US-10472328-B2 | PKM2 modulators and methods for their use | TOLERO PHARMACEUTICALS, INC. (US) | 2019-11-12 | — | — | US | disclosed |
| US-20190119219-A1 | PKM2 MODULATORS AND METHODS FOR THEIR USE | SUMITOMO PHARMA ONCOLOGY, INC. | 2019-04-25 | — | — | US | disclosed |
| US-10207996-B2 | PKM2 modulators and methods for their use | TOLERO PHARMACEUTICALS, INC. (US) | 2019-02-19 | — | — | US | disclosed |
| US-20170015631-A1 | PKM2 MODULATORS AND METHODS FOR THEIR USE | SUMITOMO PHARMA ONCOLOGY, INC. | 2017-01-19 | — | — | US | disclosed |
| US-6852717-B2 | Compounds useful as anti-inflammatory agents | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-02-08 | — | — | US | disclosed |
| US-6825184-B2 | FOR USE AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-11-30 | — | — | US | disclosed |
| EP-1438048-A1 | 1,4-DISUBSTITUTED BENZO-FUSED UREA COMPOUNDS AS CYTOKINE INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2004-07-21 | — | — | EP | disclosed |
| US-20030162968-A1 | 1,4-Disubstituted benzo-fused urea compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-08-28 | — | — | US | disclosed |
| WO-2003032989-A1 | 1,4-DISUBSTITUTED BENZO-FUSED UREA COMPOUNDS AS CYTOKINE INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2003-04-24 | — | — | WO | disclosed |
| US-20030008868-A1 | Compounds useful as anti-inflammatory agents | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2003-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030008868-A1 | Compounds useful as anti-inflammatory agents | TNF, MPO, PTGES | CA2 4104/4885ALDH1A1 664/4885TDP1 3045/4885 |
| US-20030162968-A1 | 1,4-Disubstituted benzo-fused urea compounds | NFKBIA, MPO, RELA | CA2 3311/4885ALDH1A1 89/4885TDP1 1233/4885 |
| US-10766865-B2 | PKM2 modulators and methods for their use | PDK1, PDK2, PKM | CA2 2766/4885ALDH1A1 2333/4885TDP1 969/4885 |
| US-10472328-B2 | PKM2 modulators and methods for their use | PDK1, PDK2, PKM | CA2 2766/4885ALDH1A1 2333/4885TDP1 969/4885 |
| US-20170015631-A1 | PKM2 MODULATORS AND METHODS FOR THEIR USE | PDK1, PDK2, PKM | CA2 2766/4885ALDH1A1 2333/4885TDP1 969/4885 |
| US-10207996-B2 | PKM2 modulators and methods for their use | PDK1, PDK2, PKM | CA2 2766/4885ALDH1A1 2333/4885TDP1 969/4885 |
| US-20200237766-A1 | PKM2 ACTIVATORS IN COMBINATION WITH REACTIVE OXYGEN SPECIES FOR TREATMENT OF CANCER | PDK1, PDK2, PCK2 | CA2 1452/4885ALDH1A1 978/4885TDP1 1541/4885 |
| US-20190119219-A1 | PKM2 MODULATORS AND METHODS FOR THEIR USE | PDK1, PDK2, PKM | CA2 2766/4885ALDH1A1 2333/4885TDP1 969/4885 |
| US-20210002233-A1 | PKM2 MODULATORS AND METHODS FOR THEIR USE | PDK1, PDK2, PKM | CA2 2766/4885ALDH1A1 2333/4885TDP1 969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.